promise pharmacy tirzepatide Tirzepatide-Weightloss Compounded Tirzepatide - APEX MEDICAL

Semaglutide is a long-acting glucagon-like peptide 1 (GLP-1) agonist, while tirzepatide is both a GLP-1 agonist and a glucose dependent insulinotropic polypeptide (GIP)

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro

Nausea affects up to 25% of tirzepatide users during the first weeks of treatment

Patients who stopped taking GLP-1 weight-loss medications regained weight four times as fast as those using alternative methods.

Caloric intake reduction: The combined effect leads to a meaningful reduction in daily calorie consumption over time

Lilly is testing whether tirzepatide can move beyond weight loss and become part of an immunometabolism strategy for chronic immune-inflammatory diseases.